Global healthcare company Viatris has announced that its proposed treatment for blepharitis has failed its Phase 3 Study.
The study was evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) for blepharitis but did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing.
The MR-139 3001 Phase 3 trial consisted of a randomised, placebo-controlled, double-masked prospective study, with a total of 477 patients who were randomised to receive either MR-139 or placebo, self-administered to the eyelids twice daily, treated and observed over 12 weeks.
The study… did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing.
Viatris Chief Research and Development Officer Philippe Martin said that given the study “did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 programme, which may include revising the planned additional phase 3 study”. 1
Reference
- Viatris, Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis (media release, 18 July 2025) available at: newsroom.viatris.com/2025-07-18-Viatris-Provides-Update-on-Phase-3-Study-of-MR-139-for-Blepharitis [accessed July 2025].
